CN117897144A - 用于透皮施用胍法辛的包含胍法辛和一元羧酸的透皮治疗系统 - Google Patents

用于透皮施用胍法辛的包含胍法辛和一元羧酸的透皮治疗系统 Download PDF

Info

Publication number
CN117897144A
CN117897144A CN202280059240.1A CN202280059240A CN117897144A CN 117897144 A CN117897144 A CN 117897144A CN 202280059240 A CN202280059240 A CN 202280059240A CN 117897144 A CN117897144 A CN 117897144A
Authority
CN
China
Prior art keywords
guanfacine
silicone
layer
amount
containing layer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280059240.1A
Other languages
English (en)
Chinese (zh)
Inventor
E-M·普恩兹
M·埃姆根布罗奇
P·莫尔
S·洛尔沙伊特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lts Roman Treatment System Co ltd
Original Assignee
Lts Roman Treatment System Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lts Roman Treatment System Co ltd filed Critical Lts Roman Treatment System Co ltd
Publication of CN117897144A publication Critical patent/CN117897144A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7069—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained otherwise than by reactions only involving carbon to carbon unsaturated bonds, e.g. polysiloxane, polyesters, polyurethane, polyethylene oxide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN202280059240.1A 2021-08-30 2022-08-29 用于透皮施用胍法辛的包含胍法辛和一元羧酸的透皮治疗系统 Pending CN117897144A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP21193889 2021-08-30
EP21193889.9 2021-08-30
PCT/EP2022/073922 WO2023031103A1 (en) 2021-08-30 2022-08-29 Transdermal therapeutic system for the transdermal administration of guanfacine comprising guanfacine and a mono-carboxylic acid

Publications (1)

Publication Number Publication Date
CN117897144A true CN117897144A (zh) 2024-04-16

Family

ID=77563915

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280059240.1A Pending CN117897144A (zh) 2021-08-30 2022-08-29 用于透皮施用胍法辛的包含胍法辛和一元羧酸的透皮治疗系统

Country Status (6)

Country Link
US (1) US20240374544A1 (cg-RX-API-DMAC7.html)
EP (1) EP4395749B1 (cg-RX-API-DMAC7.html)
JP (1) JP7898514B2 (cg-RX-API-DMAC7.html)
CN (1) CN117897144A (cg-RX-API-DMAC7.html)
CA (1) CA3226214A1 (cg-RX-API-DMAC7.html)
WO (1) WO2023031103A1 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026158595A1 (zh) * 2025-01-25 2026-07-30 湖南派格兰药业有限公司 一种化合物i贴剂组合物、化合物i贴剂及其制备方法

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117379398A (zh) * 2023-11-29 2024-01-12 长沙晶易医药科技股份有限公司 一种胍法辛透皮贴剂及其制备方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07145048A (ja) * 1993-11-25 1995-06-06 Sekisui Chem Co Ltd 医療用貼付剤
KR101432698B1 (ko) 2006-06-06 2014-08-22 다우 코닝 코포레이션 실리콘 아크릴레이트 하이브리드 조성물
MX353752B (es) * 2009-01-20 2018-01-26 Los Angeles Biomedical Res Inst Harbor Ucla Medical Ct Los ácidos sórbico y benzoico y sus derivados aumentan la actividad de un neurofármaco.
RU2544702C2 (ru) 2009-04-24 2015-03-20 Хенкель Корпорейшн Клеи на основе силикон-акрилового гибридного полимера
JP2013139554A (ja) 2011-11-29 2013-07-18 Dow Corning Corp シリコーンアクリレートハイブリッド組成物及び該組成物の製造方法
KR102048682B1 (ko) 2015-02-09 2019-11-27 다우 실리콘즈 코포레이션 다중상 실리콘 아크릴 하이브리드 점탄성 조성물 및 이의 제조 방법
CN107427509B (zh) * 2015-08-29 2021-06-15 美德阿利克斯株式会社 含有碱性药物和山梨酸的经皮吸收组成物
CA3079694A1 (en) * 2017-10-11 2019-04-18 Dow Silicones Corporation Transdermal therapeutic system for the transdermal administration of guanfacine comprising a silicone acrylic hybrid polymer
BR112020007011A2 (pt) * 2017-10-11 2020-10-06 Lts Lohmann Therapie-Systeme Ag sistema terapêutico transdérmico para a administração transdérmica de guanfacina compreendendo pelo menos um aditivo
JP2021517569A (ja) * 2018-03-13 2021-07-26 エルテーエス ローマン テラピー−ジステーメ アーゲー シリコーンアクリルハイブリッドポリマーを含む、ブプレノルフィンの経皮投与のための経皮治療システム

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026158595A1 (zh) * 2025-01-25 2026-07-30 湖南派格兰药业有限公司 一种化合物i贴剂组合物、化合物i贴剂及其制备方法

Also Published As

Publication number Publication date
JP2024532418A (ja) 2024-09-05
EP4395749B1 (en) 2025-11-19
JP7898514B2 (ja) 2026-07-31
EP4395749C0 (en) 2025-11-19
CA3226214A1 (en) 2023-03-09
EP4395749A1 (en) 2024-07-10
US20240374544A1 (en) 2024-11-14
WO2023031103A1 (en) 2023-03-09

Similar Documents

Publication Publication Date Title
JP7660162B2 (ja) シリコーンポリマーを含むグアンファシンの経皮投与のための経皮治療システム
CN111447926B (zh) 用于透皮施用胍法辛的包含至少一种添加剂的透皮治疗系统
JP7659589B2 (ja) シリコーンアクリルハイブリッドポリマーを含むグアンファシンの経皮投与のための経皮治療システム
EP4395749B1 (en) Transdermal therapeutic system for the transdermal administration of guanfacine comprising guanfacine and a mono-carboxylic acid
CN111093639A (zh) 用于卡巴拉汀经皮给药的经皮治疗系统
CN110809466A (zh) 含东莨菪碱和硅氧烷丙烯酸杂化聚合物的经皮治疗系统
RU2812734C2 (ru) Трансдермальная терапевтическая система для трансдермального введения гуанфацина, содержащая по меньшей мере одно вспомогательное вещество
HK40109888B (en) Transdermal therapeutic system for the transdermal administration of guanfacine comprising guanfacine and a mono-carboxylic acid
HK40109888A (en) Transdermal therapeutic system for the transdermal administration of guanfacine comprising guanfacine and a mono-carboxylic acid
RU2792822C2 (ru) Трансдермальная терапевтическая система для трансдермального введения гуанфацина, содержащая силиконовый полимер
HK40034304A (en) Transdermal therapeutic system for the transdermal administration of guanfacine comprising at least one additive
HK40034304B (en) Transdermal therapeutic system for the transdermal administration of guanfacine comprising at least one additive
HK40028675A (en) Transdermal therapeutic system for the transdermal administration of rivastigmine

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination